PFParaskevi Farmaki

Paraskevi Farmaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paraskevi Farmaki has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Anna Garmpi

    Internal Medicine Department, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens. Greece

    2 shared publications
  • Eleni Memi

    Unit of Endocrinology, Diabetes Mellitus and Metabolism, Aretaieion

    2 shared publications
  • Georgios Kyriakos

    Seccion de Endocrinologia y Nutrition, Hospital General Universitario Santa Lucia, Cartagena. Spain

    2 shared publications
  • Konstantina Kyre

    Internal Medicine Department, KAT General Hospital, Athens. Greece

    2 shared publications
  • Spyridon Savvanis

    Department of Internal Medicine General Hospital of Athens "Elpis", Athens. Greece

    2 shared publications
  • Afroditi Nonni

    First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

    1 shared publication

Latest Publications

  • Open Access

    SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study

    by Georgios Kyriakos, Lourdes V. Quiles-Sanchez, Anna Garmpi, Paraskevi Farmaki, Konstantina Kyre, Spyridon Savvanis, Vasileios K. Antoniou, Eleni Memi

    A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied.


  • Open Access

    Cardiovascular and Renal Outcomes of Incretin-based Therapies: A Review of Recent Clinical Trials

    by Georgios Kyriakos, Lourdes Victoria Quiles-Sanchez, Anna Garmpi, Paraskevi Farmaki, Konstantina Kyre, Spyridon Gkogkos, Spyridon Savvanis, Eleni Memi

    Background: To report the cardiovascular and renal effects of incretin-based therapies. Method: The studies of clinical trials on incretin-based therapy published in medical journals from the years 2010 to 2017 were comprehensively searched using MEDLINE and EMBASE with no language restriction. The studies were reviewed and the cardiovascular and renal risks reported were recorded. Results: Incretin-based therapeutics represent novel and promising anti-diabetes drugs, the direct cardiovascular actions which may translate into demonstrable clinical benefits on cardiovascular outcomes. Furthermore, incretin-based therapies do not adversely affect renal function.


  • Open Access

    Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities

    by Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Vasiliki E. Georgakopoulou, Panagiotis Sarantis, Efstathios A. Antoniou, Michalis V. Karamouzis, Afroditi Nonni, Dimitrios Schizas, Evangelos Diamantis, et al.

    Hepatocellular carcinoma (HCC) remains a major health problem worldwide with a continuous increasing prevalence. Despite the introduction of targeted therapies like the multi-kinase inhibitor sorafenib, treatment outcomes are not encouraging. The prognosis of advanced HCC is still dismal, underlying the need for novel effective treatments. Apart from the various risk factors that predispose to the development of HCC, epigenetic factors also play a functional role in tumor genesis. Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histone lysine residues of proteins, such as the core nucleosome histones, in this way not permitting DNA to loosen from the histone octamer and consequently preventing its transcription. Considering that HDAC activity is reported to be up-regulated in HCC, treatment strategies with HDAC inhibitors (HDACIs) showed some promising results. This review focuses on the use of HDACIs as novel anticancer agents and explains the mechanisms of their therapeutic effects in HCC.